An van Es-Johansson
Independent DirectorDr. An van Es-Johansson, also known Annigje, M.D., served as Independent Director of Lumos Pharma, Inc. since February 16, 2021. Since 2021 she is a Senior Advisor for Sinfonia AB. Dr. van Es-Johansson served as Head of Development at AlzeCure Pharma AB (publ) since March 3, 2020 until 2021. Dr. van Es-Johansson served as the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer disease from September 2018 to March 2021 and serves as Senior Advisor. Dr. van Es-Johansson has been an Independent Director at Savara Pharmaceuticals Inc. since December 3, 2019. Dr. van Es-Johansson served as an Independent Director of Medivir AB (publ) since May 9, 2019 until May 05, 2022. Dr. van Es-Johansson had been Member of Scientific Board at Cerenome, Inc. (formerly known as Plus Therapeutics, Inc.) Dr. van Es-Johansson also served as a Member of the Scientific Advisory Board for Uppsala Bio from 2004 to 2016. She is Director of Agendia BV. She is an Independent Director of Cerenome, Inc. (formerly known as Plus Therapeutics, Inc.) since January 1, 2020. Dr. van Es-Johansson served as an Independent Director of BioInvent International AB since May 23, 2016 until February 15, 2021. She served as Independent Advisor at BioInvent International AB (publ) since February 15, 2021 until February 2021. Dr. van Es-Johansson has a long, international experience within the life science sector and has held several leading positions within Clinical Development, Medical Affairs, Business Development and Commercial at Pharmacia and Sobi in Sweden including as Vice President and Head of EMENAR Medical Affairs for Specialty Care and Partner Products from March 2013 to January 2018. Prior to Sobi, Dr. van Es-Johansson served in leadership positions within large pharmaceutical and smaller biotechnology companies, including Roche, Eli Lilly, Active Biotech and BioStratum. From 2004 to 2016, she was a Member of the Scientific Adboard for Uppsala Bio. Dr. van Es-Johansson is also an entrepreneur and professional coach. Dr. van Es-Johansson served as a Director of AlzeCure Pharma AB (publ) from 2017 to March 3, 2020. From 2005 to 2018, Dr. van Es-Johansson served in a range of executive roles of increasing responsibility at Swedish Orphan Biovitrum AB (Sobi). Dr. van Es-Johansson has leadership experience within large pharmaceutical and smaller biotechnology companies, including Roche, Eli Lilly, Active Biotech and BioStratum. Dr. van Es-Johansson holds an MD from the Erasmus University, Rotterdam, The Netherlands.
Positions
- Company NameCerenome, Inc.Stock CodeCNSYPositionIndependent DirectorColleagues
- MHMarc H. HedrickPresident, CEO & Director
- RJRichard J. HawkinsIndependent Chairman of the Board
- AJAndrew J. SimsVP & CFO
- EJEric J. DanielsChief Development Officer & COO
- RHRuss HavranekExecutive Vice President of Commercial and Corporate Strategy
- RARonald A. AndrewsChief Business Officer & Director
- HCHoward ClowesIndependent Director
